drugset / Trial / NCT06220162
VAC Regimen for AML Patients Who Failed to Response to VA Regimen
Phase 2
Recruiting
32 enrolled
The First Affiliated Hospital of Soochow University
Affiliated Hospital of Nantong University · collabJining Medical University · collabNorthern Jiangsu People's Hospital · collabThe First Affiliated Hospital of Bengbu Medical University · collabThe Second People's Hospital of Huai'an · collab
NaSingle-groupOpen-labelTreatment
Summary
Chidamide in combination with venetoclax and azacitidine (VAC) were expected to improve remission rate of patients following to VA regimen treatment failure.
Timeline
- Start
- 2024-02-01
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tucidinostat | Small molecule | 10 mg | — |
| Background | Azacitidine | Other / unclassified | 75 mg/m2 | — |
| Background | Venetoclax | Small molecule | 400 mg | Oral |